Managers

Blue Delta Capital Partners is seeking $125 mln for second fund

Blue Delta Capital Partners, a McLean, Virginia-based venture firm focused on U.S. government technology market, is raising $125 million for its second fund, according to a filing with the SEC.

Leuko secures $1.8 mln seed

Boston and Madrid-based Leuko, a developer of a non-invasive white blood cell monitoring device, has raised $1.8 million in seed financing. The investors included Good Growth Capital, Pegasus Tech Ventures and Nina Capital.

Fund Performance: Longitude, DCM, Bay lead venture portfolio at LA pension

Fifth Wall raises $503 mln from 50 LPs for real estate investing

Orum Therapeutics reels in $30 mln Series B

Cambridge, Massachusetts-based Orum Therapeutics, a biotech firm, has secured $30 million in Series B financing. The investors were IMM Investment, Smilegate Investment, KTB Network, Stassets Investment, InterVest and KB Investment/Solidus Investment.

Cradle Genomics attracts $17.1 mln

San Diego-based Cradle Genomics, a provider of a prenatal testing methodology, has secured $17.1 million in funding. Illumina Ventures and Section 32 led the round with participation from Alexandria Real Estate Equities, Sea Lane Ventures, Listwin Ventures and Axon Ventures.

Pyxis Oncology rakes in $22 mln Series A

Boston-based Pyxis Oncology, a newly formed immuno-oncology company, has raised $22 million in Series A funding. Leaps by Bayer led the round with participation from other investors that included Agent Capital, Ipsen and Longwood Fund.

VC-backed Pandion Therapeutics appoints CEO

Cambridge, Massachusetts-based Pandion Therapeutics, a biotech company focused on treating autoimmune and inflammatory disease, has named Dr. Rahul Kakkar as CEO and a member of its board of directors. Also, Pandion has promoted Dr. Jo Viney, a founder of the company, to president and chief scientific officer. And, Vikas Goyal joins Pandion as senior vice president of business development. Pandion's investors include Polaris Partners, Versant Ventures, Roche Venture Fund, SR One and BioInnovation Capital.

Vida Ventures raised $537 mln toward a second fund

Vida Ventures, a Boston, Massachusetts-based life sciences-focused venture firm raised $537 million towards its second fund, according to a regulatory document.

Vice Ventures looks to raise additional $25 mln for cannabis, sextech and alcohol deals